胃癌肝转移辅助腹腔化疗的生存分析

Survival Analysis of Hepatic Metastasis in Gastric Carcinoma Adjuvant Intraperitoneal Chemotherapy

目的探讨胃癌肝转移辅助腹腔化疗的疗效和不良反应。方法采用比较分析方法,对48名胃癌肝转移患者随机分组,分别进行腹腔化疗和静脉辅助化疗两种方案,通过观察患者的生存时间和化疗的毒副反应,采用卡方检验和生存分析不同化疗方案与患者病情的关系。结果胃癌肝转移加用腹腔化疗延长了生存时间,而毒副反应并不增加,效果较好。结论胃癌肝转移静脉联合腹腔化疗,较单纯静脉化疗,疗效较好,且耐受性较好。

Objective To explore the curative effect and adverse reaction of hepatic metastasis in gastric carcinoma adjuvant intraperitoneal chemotherapy.Methods By using comparative analysis method,48 cases with hepatic metastasis in gastric carcinoma were randomly assigned to be treated with intraperitoneal chemotherapy and intravenous chemotherapy.By observing the living time and the chemotherapy toxicity of patients,chi-square and survival analysis were used to explore the relationship of different chemotherapy regimens and patient conditions.Results The curative effect of treating hepatic metastasis in gastric carcinoma with intraperitoneal chemotherapy was good,which prolonged the living time while the toxicity didn＇t increase.Conclusion Compared with intravenous chemotherapy,the curative effect of hepatic metastasis in gastric carcinoma with intraperitoneal chemotherapy is better and well tolerated.